Forte Biosciences Inc (FBRX) - Total Assets
Based on the latest financial reports, Forte Biosciences Inc (FBRX) holds total assets worth $97.09 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See FBRX net asset value for net asset value and shareholders' equity analysis.
Forte Biosciences Inc - Total Assets Trend (2015–2024)
This chart illustrates how Forte Biosciences Inc's total assets have evolved over time, based on quarterly financial data.
Forte Biosciences Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Forte Biosciences Inc's total assets of $97.09 Million consist of 99.7% current assets and 0.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 36.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Forte Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Forte Biosciences Inc stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Forte Biosciences Inc's current assets represent 99.7% of total assets in 2024, an increase from 96.8% in 2015.
- Cash Position: Cash and equivalents constituted 36.1% of total assets in 2024, up from 13.1% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Forte Biosciences Inc Competitors by Total Assets
Key competitors of Forte Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Forte Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.34 | 2.06 | 26.52 |
| Quick Ratio | 7.34 | 2.06 | 26.52 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $82.42 Million | $9.09 Million | $57.64 Million |
Forte Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Forte Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.71 |
| Latest Market Cap to Assets Ratio | 2.80 |
| Asset Growth Rate (YoY) | 57.9% |
| Total Assets | $61.56 Million |
| Market Capitalization | $172.07 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Forte Biosciences Inc's assets at a significant premium (2.80x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Forte Biosciences Inc's assets grew by 57.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Forte Biosciences Inc (2015–2024)
The table below shows the annual total assets of Forte Biosciences Inc from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $61.56 Million | +57.93% |
| 2023-12-31 | $38.98 Million | -7.18% |
| 2022-12-31 | $42.00 Million | -3.02% |
| 2021-12-31 | $43.31 Million | -29.28% |
| 2020-12-31 | $61.24 Million | +699.67% |
| 2019-12-31 | $7.66 Million | -92.57% |
| 2018-12-31 | $103.08 Million | +11.96% |
| 2017-12-31 | $92.07 Million | +160.45% |
| 2016-12-31 | $35.35 Million | -43.14% |
| 2015-12-31 | $62.17 Million | -- |
About Forte Biosciences Inc
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. … Read more